FFC#11/2019

Functional role of post-translational modifications in F508del-CFTR correction

FFC#11/2019

Functional role of post-translational modifications in F508del-CFTR correction.

PRINCIPAL INVESTIGATOR

Mauro Salvi (Università di Padova, Dipartimento di Scienze Biomediche)

RESEARCHERS

3

CATEGORY

AREA 1 Therapies to correct the underlying defect

DURATION

1 year

GOAL

€ 40.000 €

RESULTS

Post-translational modifications (PTM) are biochemical reactions on proteins that physiologically take place in the cell. Also, CFTR can be modified with different PTMs, such as methylation/de-methylation, phosphorylation or ubiquitination. For CFTR, PTMs called “PTM-code”, correspond to the modifications needed for the maturation of CFTR-F508del.
To understand which of these PTM-codes were necessary for the recovery of the mutated CFTR-F508del function, the researchers modified one by one and then all together, the CFTR sites on which the PTM-codes occur. The CFTR-F508del gene was modified in the positions corresponding to the PTM-code and inserted in human bronchial epithelial cells (CFBE41o−) treated with VX-445 (elexacaftor) and VX-661 (tezacaftor). The consequences of these changes were subsequently observed on the cells in combination with treatment with correctors. The experiments led the researchers to hypothesize that the PTM-code is not required for the correction of CFTR-F508del, which is in fact restored by the correctors regardless of the mutations on the PTM-code. The researchers then identified 3 demethylases (enzymes involved in methylation, one of the post-translational modifications) whose expression reduction would favour the corrector-induced functional recovery of CFTR-F508del. In the extension of the project (FFC#7/2020) the mechanisms through which methylation regulates the maturation of CFTR-F508del will be investigated.

Pubblications

  • Salvi M, Non-Histone Protein Methylation: Molecular Mechanisms and Physiopathological Relevance, Curr Protein Pept Sci, 2020;21(7):640-641

OTHER RESULTS

FFC#1/2023

Tezacaftor, one of the components of Kaftrio, induces an accumulation of dihydroceramides both in vitro and in vivo in animal models

FFC#4/2023

Pseudopaline–aztreonam conjugates exhibited enhanced antimicrobial activity against Pseudomonas aeruginosa compared to aztreonam alone

FFC#10/2023

Several drugs already approved for human use inhibit the growth of P. aeruginosa, its virulence, or its ability to form biofilms in vitro